Side-by-side · Research reference
KPVvsP21
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongAUTO-DRAFTED13/39 cited
BAnimal-MechanisticHUMAN-REVIEWED8/36 cited
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
P21
CNTF-Derived Neuropeptide · Animal Model Evidence
Animal onlyEvidence level
SQ · Site unspecified · Frequency unknown
01Mechanism of Action
Parameter
KPV
P21
Primary target
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
CNTF receptor alpha (CNTFRα) / LIF receptor (LIFR) / gp130 complex on neural stem cells
Pathway
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
CNTF mimetic → CNTFRα/LIFR/gp130 heterotrimer → JAK/STAT3 signaling → neurogenesis, stem cell proliferation, neuroprotection
Downstream effect
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Increased neural stem cell self-renewal, globose basal cell activation (Mash1+ cells), olfactory sensory neuron regeneration, hippocampal neurogenesis, neuroprotection in developmental disorders
Feedback intact?
No melanocortin receptor binding
—
Origin
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Small-molecule peptide mimetic derived from full-length ciliary neurotrophic factor (CNTF), designed to retain receptor activation with improved pharmacokineticsMottolese 2024
Antibody development
—
—
02Dosage Protocols
Parameter
KPV
P21
Frequency
Daily or 2–3× per week
—
Lower / starter dose
100 mcg / day
—
Evidence basis
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
Animal models only
CDKL5 KO mice, methimazole-induced olfactory injury, CNTF-/- knockout models.Mottolese 2024Cox 2026Jia 2020
Duration
4–8 weeks per cycle
Not specified
Reconstitution
Bacteriostatic water (SQ form)
—
Timing
No specific time; often taken with / before meals (oral)
—
Half-life
Hours (estimated; rapid tissue uptake)
—
Human dosing
—
No established protocol
No clinical trial data available.
Animal models (mice)
—
Dose and route not specified in abstractsMottolese 2024Jia 2020
In vitro and in vivo studies demonstrate efficacy; precise dosing protocols not disclosed.
Route
—
Presumed subcutaneous or intraperitoneal (animal studies)
04Side Effects & Safety
Parameter
KPV
P21
Injection site reaction
Mild irritation
—
GI symptoms
Rare nausea (oral form)
—
Long-term safety
Limited human data
—
Pregnancy / OB
Avoid — insufficient data
—
Human safety data
—
None available
No clinical trials in humans.
Animal tolerability
—
Well-tolerated in mouse models; no toxicity reported in available abstracts
Theoretical risks
—
Uncontrolled stem cell proliferation, immune response to peptide, unknown long-term CNS effects
Absolute Contraindications
KPV
- ·Pregnancy / breastfeeding
P21
- ·Use in humans not validated
Relative Contraindications
KPV
- ·Active autoimmune disease (theoretical)
P21
- ·Active malignancy (theoretical — neurotrophic signaling may affect tumour growth)
- ·Pregnancy or lactation (no safety data)
05Administration Protocol
Parameter
KPV
P21
1. Reconstitution
Add 1 mL bacteriostatic water to vial per labelling.
Not established. No FDA approval, no clinical trial data.
2. Form
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
In vivo studies used systemic administration (route not specified in abstracts) in mouse models of neurodegeneration, olfactory injury, and CDKL5 deficiency disorder. In vitro studies used primary cell cultures.
3. Timing
Morning preferred; oral form taken with / before meals.
—
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
—
5. Needle
29–31G insulin syringe (SQ form).
—
06Stack Synergy
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions
P21
— no documented stacks